Colorectal cancer (CRC) is the most commonly diagnosed cancer among Saudi males and ranks third in females with up to 73% of cases diagnosed at late stage. This review provides an analysis of CRC situation in the Kingdom of Saudi Arabia (KSA) from healthcare perspective. A PUBMED (1986–2018) search was done to identify publications focusing on CRC in KSA. Due to reports of increased CRC incidence among young age group (< 50), and given the young population of KSA, the disease may burden the national healthcare system in the next decades. Environmental factors attributed to increasing incidence rates of CRC include red meat consumption, sedentary lifestyle, and increased calorie intake. Despite substantial investment in healthcare, attention to predictive diagnostics and targeted prevention is lacking. There is a need to develop national screening guidelines based on evidence that supports a reduction in incidence and mortality of CRC when screening is implemented. Future approaches are discussed based on multi-level diagnostics, risk assessment, and population screening programs focused on the needs of young populations that among others present the contents of the advanced approach by predictive, preventive, and personalized medicine. Recommendations are provided that could help to develop policies at regional and national levels. Countries with demographics and lifestyle similar to KSA may gain insights from this review to shape their policies and procedures.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
World Health Organization, Cancer Country Profile - World Health Organization. 2014.
KFSHRC, O.C.R.U., TUMOR REGISTRY ANNUAL REPORT 2014. 2017.
Aziz MA, Allah-Bakhsh H. Colorectal cancer: a looming threat, opportunities, and challenges for the Saudi population and its healthcare system. Saudi J Gastroenterol. 2018;24(3):196–7.
Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation-EPMA position paper 2016. EPMA Journal. 2016;7(1):23.
Golubnitschaja, O., V. Costigliola, and Epma, General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J, 2012. 3(1): p. 14.
Ng SW, et al. The prevalence and trends of overweight, obesity and nutrition-related non-communicable diseases in the Arabian Gulf States. Obes Rev. 2011;12(1):1–13.
The Lancet O. Addressing the burden of cancer in the Gulf. Lancet Oncol. 2014;15(13):1407.
Alsanea N, Abduljabbar AS, Alhomoud S, Ashari LH, Hibbert D, Bazarbashi S. Colorectal cancer in Saudi Arabia: incidence, survival, demographics and implications for national policies. Ann Saudi Med. 2015;35(3):196–202.
Bazarbashi S, Al Eid H, Minguet J. Cancer incidence in Saudi Arabia: 2012 data from the Saudi Cancer Registry. Asian Pac J Cancer Prev. 2017;18(9):2437–44.
Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. Int J Cancer. 2011;128(7):1668–75.
Siegel RL, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
Ahnen DJ, Wade SW, Jones WF, Sifri R, Mendoza Silveiras J, Greenamyer J, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89(2):216–24.
Imperiale TF. The rising prevalence of early-onset colorectal cancer: ready and FIT to tackle? Gastrointest Endosc. 2017;86(5):900–2.
McKay A, Donaleshen J, Helewa RM, Park J, Wirtzfeld D, Hochman D, et al. Does young age influence the prognosis of colorectal cancer: a population-based analysis. World J Surg Oncol. 2014;12:370.
Guraya SY, Eltinay OE. Higher prevalence in young population and rightward shift of colorectal carcinoma. Saudi Med J. 2006;27(9):1391–3.
Bailey CE, Hu CY, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015;150(1):17–22.
Isbister WH. Colorectal cancer below age 40 in the Kingdom of Saudi Arabia. Aust N Z J Surg. 1992;62(6):468–72.
Mosli MH, Al-Ahwal MS. Colorectal cancer in the Kingdom of Saudi Arabia: need for screening. Asian Pac J Cancer Prev. 2012;13(8):3809–13.
O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003;69(10):866–72.
Zahir MN, et al. Clinical features and outcome of sporadic colorectal carcinoma in young patients: a cross-sectional analysis from a developing country. ISRN Oncol. 2014;2014:461570.
Doll R, Payne P, Waterhouse J. Cancer incidence in five continents. 1966. 1966. Berlin Springer CrossRef Google Scholar.
Al-Ahmadi K, Al-Zahrani A. NO(2) and cancer incidence in Saudi Arabia. Int J Environ Res Public Health. 2013;10(11):5844–62.
Di Sarsina PR, Tassinari M. Person-centred healthcare and medicine paradigm: it’s time to clarify. EPMA Journal. 2015;6(1):11.
Alamri FA, Saeedi MY, Kassim KA. Dietary and other risk factors for colo-rectal cancer in Saudi Arabia. J Med Med Sci. 2014;5:222–9.
Arafa MA, Farhat K. Colorectal cancer in the Arab world—screening practices and future prospects. Asian Pac J Cancer Prev. 2015;16(17):7425–30.
Azzeh FS, Alshammari EM, Alazzeh AY, Jazar AS, Dabbour IR, el-Taani HA, et al. Healthy dietary patterns decrease the risk of colorectal cancer in the Mecca Region, Saudi Arabia: a case-control study. BMC Public Health. 2017;17(1):607.
Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999;91(11):916–32.
Musaiger AO. Diet and prevention of coronary heart disease in the Arab Middle East countries. Med Princ Pract. 2002;11(Suppl 2):9–16.
Moradi-Lakeh M, el Bcheraoui C, Afshin A, Daoud F, AlMazroa MA, al Saeedi M, et al. Diet in Saudi Arabia: findings from a nationally representative survey. Public Health Nutr. 2017;20(6):1075–81.
Organization, W.H., Noncommunicable diseases country profiles 2014. 2014.
Terry PD, Miller AB, Rohan TE. Prospective cohort study of cigarette smoking and colorectal cancer risk in women. Int J Cancer. 2002;99(3):480–3.
Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC, et al. Comparison of risk factors for colon and rectal cancer. Int J Cancer. 2004;108(3):433–42.
Al-Othman S, et al. Tackling cancer control in the gulf cooperation council countries. The Lancet Oncology. 2015;16(5):e246–57.
Abdulmalik M and Thavorncharoensap M.. Burden of cancer attributable to smoking in Gulf Cooperation Council (GCC) countries. in Proceedings of the International Conference on Applied Science and Health. 2018.
Doubeni CA, Major JM, Laiyemo AO, Schootman M, Zauber AG, Hollenbeck AR, et al. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst. 2012;104(18):1353–62.
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer—viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–8.
Boyle T, Keegel T, Bull F, Heyworth J, Fritschi L. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(20):1548–61.
Song JH, Kim YS, Yang SY, Chung SJ, Park MJ, Lim SH, et al. Physical activity and other lifestyle factors in relation to the prevalence of colorectal adenoma: a colonoscopy-based study in asymptomatic Koreans. Cancer Causes Control. 2013;24(9):1717–26.
Kruijsen-Jaarsma M, et al. Effects of exercise on immune function in patients with cancer: a systematic review. Exerc Immunol Rev. 2013;19.
Zheng Q, Cui G, Chen J, Gao H, Wei Y, Uede T, et al. Regular exercise enhances the immune response against microbial antigens through up-regulation of toll-like receptor signaling pathways. Cell Physiol Biochem. 2015;37(2):735–46.
Li T, Wei S, Shi Y, Pang S, Qin Q, Yin J, et al. The dose-response effect of physical activity on cancer mortality: findings from 71 prospective cohort studies. Br J Sports Med. 2016;50(6):339–45.
Al-Daghri NM, et al. Diabetes mellitus type 2 and other chronic non-communicable diseases in the central region, Saudi Arabia (Riyadh cohort 2): a decade of an epidemic. BMC Med. 2011;9(1):76.
Alotaibi A, Perry L, Gholizadeh L, al-Ganmi A. Incidence and prevalence rates of diabetes mellitus in Saudi Arabia: an overview. J Epidemiol Glob Health. 2017;7(4):211–8.
Alhyas L, McKay A, Majeed A. Prevalence of type 2 diabetes in the States of the co-operation council for the Arab States of the Gulf: a systematic review. PLoS One. 2012;7(8):e40948.
Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58(3):130–60.
Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329(27):1977–81.
Alberts DS, Martínez ME, Roe DJ, Guillén-Rodríguez JM, Marshall JR, van Leeuwen JB, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. N Engl J Med. 2000;342(16):1156–62.
Robertson DJ, Greenberg ER, Beach M, Sandler RS, Ahnen D, Haile RW, et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology. 2005;129(1):34–41.
Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366(8):687–96.
Lin, J., et al., Screening for colorectal cancer: an updated systematic review for the U.S. Preventive Services Task Force. 2015.
Beydoun HA, Beydoun MA. Predictors of colorectal cancer screening behaviors among average-risk older adults in the United States. Cancer Causes Control. 2008;19(4):339–59.
McLachlan SA, Clements A, Austoker J. Patients’ experiences and reported barriers to colonoscopy in the screening context—a systematic review of the literature. Patient Educ Couns. 2012;86(2):137–46.
Cole AM, Jackson JE, Doescher M. Urban-rural disparities in colorectal cancer screening: cross-sectional analysis of 1998-2005 data from the Centers for Disease Control’s Behavioral Risk Factor Surveillance Study. Cancer Med. 2012;1(3):350–6.
Ananthakrishnan AN, Hoffmann RG, Saeian K. Higher physician density is associated with lower incidence of late-stage colorectal cancer. J Gen Intern Med. 2010;25(11):1164–71.
Mainous AG, et al. The relationship between continuity of care and trust with stage of cancer at diagnosis. Fam Med. 2004;36(1):35–9.
Plascak JJ, Fisher JL, Paskett ED. Primary care physician supply, insurance type, and late-stage cancer diagnosis. Am J Prev Med. 2015;48(2):174–8.
Roetzheim RG, et al. The effects of physician supply on the early detection of colorectal cancer. J Fam Pract. 1999;48(11):850–8.
Corkum M, Urquhart R, Kendell C, Burge F, Porter G, Johnston G. Impact of comorbidity and healthcare utilization on colorectal cancer stage at diagnosis: literature review. Cancer Causes Control. 2012;23(2):213–20.
Bibbins-Domingo K, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Jama. 2016;315(23):2564–75.
Rex DK, Boland RC, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colorectal cancer screening: recommendations for physicians and patients from the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112(7):1016–30.
Provenzale D, Gupta S, Ahnen DJ, Markowitz AJ, Chung DC, Mayer RJ, et al. NCCN guidelines insights: colorectal cancer screening, version 1.2018. J Natl Compr Cancer Netw. 2018;16(8):939–49.
Wolf AM, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250–81.
Wilt TJ, Harris RP, Qaseem A. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 2015;162(10):718–25.
Care, C.T.F.o.P.H., Recommendations on screening for colorectal cancer in primary care. Cmaj, 2016. 188(5): p. 340–348.
Benard F, et al. Systematic review of colorectal cancer screening guidelines for average-risk adults: summarizing the current global recommendations. World J Gastroenterol. 2018;24(1):124–38.
Alsanea N, Almadi MA, Abduljabbar AS, Alhomoud S, Alshaban TA, Alsuhaibani A, et al. National guidelines for colorectal cancer screening in Saudi Arabia with strength of recommendations and quality of evidence. Ann Saudi Med. 2015;35(3):189–95.
Sabatino SA, White MC, Thompson TD, Klabunde CN, Centers for Disease Control and Prevention (CDC). Cancer screening test use—United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(17):464–8.
USPSTF, Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2008. 149(9): p. 627–637.
Davis T, Arnold C, Rademaker A, Bennett C, Bailey S, Platt D, et al. Improving colon cancer screening in community clinics. Cancer. 2013;119(21):3879–86.
Fenton JJ, Elmore JG, Buist DSM, Reid RJ, Tancredi DJ, Baldwin LM. Longitudinal adherence with fecal occult blood test screening in community practice. Ann Fam Med. 2010;8(5):397–401.
Whitlock EP, L.J, Liles E, Beil T, Fu R, O'Connor E, Thompson RN, Cardenas T., Screening for colorectal cancer: an updated systematic review [internet]. 2008.
Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Srivastava S, Jass JR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89(23):1758–62.
Vasen HF, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116(6):1453–6.
Alqahtani M, Grieu F, Carrello A, Amanuel B, Mashour M, Alattas R, et al. Screening for lynch syndrome in young colorectal cancer patients from Saudi Arabia using microsatellite instability as the initial test. Asian Pac J Cancer Prev. 2016;17(4):1917–23.
Aljumah AA, Aljebreen AM. Policy of screening for colorectal cancer in Saudi Arabia: a prospective analysis. Saudi J Gastroenterol. 2017;23(3):161–8.
Alhumaid A, AlYousef Z, Bakhsh HA, AlGhamdi S, Aziz MA. Emerging paradigms in the treatment of liver metastases in colorectal cancer. Crit Rev Oncol Hematol. 2018;132:39–50.
Aziz MA., Chapter 6—colorectal cancer metastasis A2 - Ahmad, Aamir, in Introduction to cancer metastasis. 2017, Academic Press. p. 95–116.
Janssens JP, Schuster K, Voss A. Preventive, predictive, and personalized medicine for effective and affordable cancer care. EPMA J. 2018;9(2):113–23.
Lu M, Zhan X. The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA J. 2018;9(1):77–102.
Cheng T, Zhan X. Pattern recognition for predictive, preventive, and personalized medicine in cancer. EPMA J. 2017;8(1):51–60.
Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, et al. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015;6(1):9.
Aziz MA, Yousef Z, Saleh AM, Mohammad S, al Knawy B. Towards personalized medicine of colorectal cancer. Crit Rev Oncol Hematol. 2017;118:70–8.
Aziz M, et al. Abstract# 2436: microarray analysis of the expression levels of molecular components of relevant signaling pathways in response to FUra/IFN-gamma treatment protocols in human colon carcinoma cell lines. Cancer Res. 2009;69(9 Supplement):2436–6.
Aziz M, Hussein M, Gabere M. Filtered selection coupled with support vector machines generate a functionally relevant prediction model for colorectal cancer. OncoTargets and Therapy. 2016;9:3313.
Aziz MA, Periyasamy S, Yousef Z, Deeb A, AlOtaibi M. Colorectal cancer driver genes identified by patient specific comparison of cytogenetic microarray. Genom Data. 2014;2:29–31.
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237–51.
Rashid, M., et al., Molecular classification of colorectal cancer using the gene expression profile of tumor samples. Exp Biol Med (Maywood), 2019: p. 1535370219850788.
Abubaker J, Bavi P, al-Harbi S, Ibrahim M, Siraj AK, al-Sanea N, et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene. 2008;27(25):3539–45.
Al-Kuraya KS, et al. Colorectal carcinoma from Saudi Arabia. Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. Saudi medical journal. 2006;27(3):323–8.
Al-Kuraya KS. KRAS and TP53 mutations in colorectal carcinoma. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2009;15(4):217–9.
Aldiab A, al Khayal KA, al Obaid OA, Alsheikh A, Alsaleh K, Shahid M, et al. Clinicopathological features and predictive factors for colorectal cancer outcome in the Kingdom of Saudi Arabia. Oncology. 2017;92(2):75–86.
Bader T, Ismail A. Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: propensity for lung metastasis. Alexandria Journal of Medicine. 2014;50(3):203–9.
Siraj AK, et al. MED12 is recurrently mutated in Middle Eastern colorectal cancer. Gut. 2018;67(4):663–71.
Alhadheq AM, et al. The effect of poly(ADP-ribose) polymerase-1 gene 3'untranslated region polymorphism in colorectal cancer risk among Saudi cohort. Dis Markers. 2016;2016:8289293.
Alshammari AH, Shalaby MA, Alanazi MS, Saeed HM. Novel mutations of the PARP-1 gene associated with colorectal cancer in the Saudi population. Asian Pac J Cancer Prev. 2014;15(8):3667–73.
Aljarbou F, Almousa N, Bazzi M, Aldaihan S, Alanazi M, Alharbi O, et al. The expression of telomere-related proteins and DNA damage response and their association with telomere length in colorectal cancer in Saudi patients. PLoS One. 2018;13(6):e0197154.
Di Leo A, et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. The lancet oncology. 2011;12(12):1134–42.
Al Obeed OA, et al., IL-17 and colorectal cancer risk in the Middle East: gene polymorphisms and expression. Cancer Manag Res, 2018. 10: p. 2653.
Gonbad RA, et al. Influence of cytokinins in combination with GA(3) on shoot multiplication and elongation of tea clone Iran 100 (Camellia sinensis (L.) O. Kuntze). ScientificWorldJournal. 2014;2014:943054.
Goerlitz D, et al. Genetic polymorphisms in NQO1 and SOD2: interactions with smoking, schistosoma infection, and bladder cancer risk in Egypt. Urol Oncol. 2014;32(1):47 e15–20.
Eldai H, Periyasamy S, al Qarni S, al Rodayyan M, Muhammed Mustafa S, Deeb A, et al. Novel genes associated with colorectal cancer are revealed by high resolution cytogenetic analysis in a patient specific manner. PLoS One. 2013;8(10):e76251.
Naser WM, Shawarby MA, al-Tamimi DM, Seth A, al-Quorain A, Nemer AMA, et al. Novel KRAS gene mutations in sporadic colorectal cancer. PLoS One. 2014;9(11):e113350.
Dadduzio V, Basso M, Rossi S, Cenci T, Capodimonti S, Strippoli A, et al. KRAS exon 2 mutations as prognostic indicators in advanced colorectal cancer in clinical practice: a mono-institutional study. Molecular diagnosis & therapy. 2016;20(1):65–74.
Laé M, Gardrat S, Rondeau S, Richardot C, Caly M, Chemlali W, et al. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways. Oncotarget. 2016;7(51):84428–38.
Arriola E, Marchio C, Tan DSP, Drury SC, Lambros MB, Natrajan R, et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Investig. 2008;88(5):491–503.
Al-Sheikh YA, et al. Expression profiling of selected microRNA signatures in plasma and tissues of Saudi colorectal cancer patients by qPCR. Oncol Lett. 2016;11(2):1406–12.
Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One. 2012;7(4):e34959.
Omrane I, Marrakchi R, Baroudi O, Mezlini A, Ayari H, Medimegh I, et al. Significant association between interleukin-17A polymorphism and colorectal cancer. Tumor Biol. 2014;35(7):6627–32.
Aziz MA, Periyasamy S, al Yousef Z, AlAbdulkarim I, al Otaibi M, Alfahed A, et al. Integrated exon level expression analysis of driver genes explain their role in colorectal cancer. PLoS One. 2014;9(10):e110134.
Deeb AM, Yousef Z, al-Johani M, Aziz MA. Effect of sampling procedure on the quality control metrics of cytoscan HD array for studying cytogenetic aspects of colorectal cancer. Int J Health Sci (Qassim). 2018;12(4):49–55.
Brawley OW. The role of government and regulation in cancer prevention. The Lancet Oncology. 2017;18(8):e483–93.
Lortet-Tieulent J, Siegel R. Expansion of cancer registration in China. Annals of translational medicine. 2014:2(7).
Aziz MA. Precision medicine in colorectal cancer. Saudi J Gastroenterol. 2019;25(2):139–40.
Lievre A, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–5.
Wilson PM, Lenz HJ. Integrating biomarkers into clinical decision making for colorectal cancer. Clin Colorectal Cancer. 2010;9(Suppl 1):S16–27.
Joseph DA, DeGroff AS, Hayes NS, Wong FL, Plescia M. The colorectal cancer control program: partnering to increase population level screening. Gastrointest Endosc. 2011;73(3):429–34.
Peterson NB, Dwyer KA, Mulvaney SA, Dietrich MS, Rothman RL. The influence of health literacy on colorectal cancer screening knowledge, beliefs and behavior. J Natl Med Assoc. 2007;99(10):1105–12.
Moiel D, Thompson J. Early detection of colon cancer-the kaiser permanente northwest 30-year history: how do we measure success? Is it the test, the number of tests, the stage, or the percentage of screen-detected patients? Perm J. 2011;15(4):30–8.
Potter MB. Strategies and resources to address colorectal cancer screening rates and disparities in the United States and globally. Annu Rev Public Health. 2013;34:413–29.
The authors declare that they have no competing interests.
Consent of publication
The incidence of CRC is rising at an alarming rate especially in affluent nations, a reflection of the prevalent dietary and lifestyle choices known to be conducive to a variety of colonic diseases. No prior study reviewed current CRC epidemiology in Saudi Arabia. Our objective is to consolidate current research on the epidemiology and prevention of CRC in Saudi Arabia.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Alyabsi, M., Alhumaid, A., Allah-Bakhsh, H. et al. Colorectal cancer in Saudi Arabia as the proof-of-principle model for implementing strategies of predictive, preventive, and personalized medicine in healthcare. EPMA Journal 11, 119–131 (2020). https://doi.org/10.1007/s13167-019-00186-x
- Predictive preventive personalized medicine, colorectal cancer
- Personalized patient profiling
- Young population
- Risk factors
- Treatment tailored to the person
- Targeted prevention, healthcare strategy, biomarkers
- Saudi Arabia